Patents by Inventor Roland Newman

Roland Newman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BI-SPECIFIC BINDING AGENTS TARGETING SYNDECAN-1 AND FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20220249679
    Abstract: Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm.
    Type: Application
    Filed: October 1, 2019
    Publication date: August 11, 2022
    Inventors: Julia CORONELLA, Robyn RICHARDSON, Anjuli TIMMER, Roland NEWMAN, Marco GYMNOPOULOS
  • CMET monoclonal binding agents, drug conjugates thereof and uses thereof
    Patent number: 11299547
    Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 12, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Vincent Blot, Marco Gymnopoulos, Anjuli Timmer, Ryo Fujita, Roland Newman
  • Syndecan-1 (CD138) binding agents and uses thereof
    Patent number: 11242403
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 8, 2022
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Julia Coronella, Robyn Richardson, Anjuli Timmer, Roland Newman
  • DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
    Publication number: 20210163604
    Abstract: Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.
    Type: Application
    Filed: March 27, 2019
    Publication date: June 3, 2021
    Inventors: Julia CORONELLA, Marco GYMNOPOULOS, Vincent BLOT, Ryo FUJITA, Roland NEWMAN
  • SYNDECAN-1 (CD138) BINDING AGENTS AND USES THEREOF
    Publication number: 20200181278
    Abstract: Presented herein, in certain embodiments, are compositions comprising binding agents that specifically bind to syndecan-1 and uses thereof.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 11, 2020
    Inventors: Julia CORONELLA, Robyn RICHARDSON, Anjuli TIMMER, Roland NEWMAN
  • CMET MONOCLONAL BINDING AGENTS, DRUG CONJUGATES THEREOF AND USES THEREOF
    Publication number: 20190330354
    Abstract: Presented herein, in certain embodiments, are compositions comprising monoclonal binding agents that specifically bind to the extracellular domain of cMET and uses thereof.
    Type: Application
    Filed: September 28, 2017
    Publication date: October 31, 2019
    Inventors: Julia CORONELLA, Vincent BLOT, Marco GYMNOPOULOS, Anjuli TIMMER, Ryo FUJITA, Roland NEWMAN
  • Antibody-fynomer conjugates
    Patent number: 10323095
    Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: June 18, 2019
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Roland Newman, Steve Granger, Michael Lyman, Dragan Grabulovski, Richard Woods, Michela Silacci, Wenjuan Zha, Isabella Attinger-Toller
  • ANTIBODY-FYNOMER CONJUGATES
    Publication number: 20170081412
    Abstract: Provided is a bi-specific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and is conjugated to an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R). The fusion polypeptide can bind to both IL-17a and IL-6R thereby suppresses, reduces, decreases, inhibits or blocks both IL-17a and IL-6R activities.
    Type: Application
    Filed: March 16, 2015
    Publication date: March 23, 2017
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Roland NEWMAN, Steve GRANGER, Michael LYMAN, Dragan GRABULOVSKI, Richard WOODS, Michela SILACCI, Wenjuan ZHA, Isabella ATTINGER-TOLLER
  • Expression and use of anti-CD20 Antibodies
    Patent number: 7744877
    Abstract: Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 29, 2010
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Anti-CD20 antibodies
    Patent number: 7422739
    Abstract: Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: September 9, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Expression and use of anti-CD20 antibodies
    Patent number: 7381560
    Abstract: Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: June 3, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Treating autoimmune diseases with humanized anti-CD40L antibody
    Patent number: 7122187
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: October 17, 2006
    Assignee: Biogen IDEC Inc.
    Inventors: Amelia Black, Nabil Hanna, Eduardo A. Padian, Roland A. Newman
  • Treating autoimmune diseases with humanized anti-CD401 antibodies
    Publication number: 20060153837
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
    Type: Application
    Filed: March 9, 2006
    Publication date: July 13, 2006
    Inventors: Amelia Black, Nabil Hanna, Eduardo Padlan, Roland Newman
  • Treating allergic diseases with humanized anti-CD40L antibody
    Patent number: 7074406
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: July 11, 2006
    Assignee: Biogen IDEC Inc.
    Inventors: Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
  • Humanized antibodies to human GP39, compositions, and therapeutic uses thereof
    Publication number: 20060147446
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.
    Type: Application
    Filed: March 9, 2006
    Publication date: July 6, 2006
    Inventors: Amelia Black, Nabil Hanna, Eduardo Padlan, Roland Newman
  • Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell Lymphoma
    Publication number: 20050186205
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chim eric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: October 4, 2004
    Publication date: August 25, 2005
    Inventors: Darrell Anderson, Nabil Hanna, John Leonard, Roland Newman, Mitchell Reff, William Rastetter
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
    Patent number: 6682734
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 27, 2004
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody
    Publication number: 20030170233
    Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.
    Type: Application
    Filed: June 17, 2002
    Publication date: September 11, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
    Publication number: 20030147885
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: September 11, 2002
    Publication date: August 7, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma
    Publication number: 20030095963
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: July 25, 2001
    Publication date: May 22, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter